Tel Aviv, Israel-based radiopharmaceutical company Starget Pharma has entered a strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT) to develop peptide radioligand therapies for cancer.
Based in Shreveport, LA, CMIT is an independent research organization and wholly owned subsidiary of the Biomedical Research Foundation of North Louisiana. Starget is developing a theranostic pair that targets a protein on cancer cells in sarcoma, neuroendocrine tumors, and malignant melanoma. The collaboration will provide Starget with the downstream capabilities required to advance the treatment through preclinical validation and into early-phase clinical development, the company said.
In addition, Starget noted that it recently closed on an $18 million funding round to support the collaboration and further expand its U.S. operations.
